EP3618819A4 - Targeted drug rescue avec de nouvelles compositions, associations et procédés correspondants - Google Patents

Targeted drug rescue avec de nouvelles compositions, associations et procédés correspondants Download PDF

Info

Publication number
EP3618819A4
EP3618819A4 EP18794381.6A EP18794381A EP3618819A4 EP 3618819 A4 EP3618819 A4 EP 3618819A4 EP 18794381 A EP18794381 A EP 18794381A EP 3618819 A4 EP3618819 A4 EP 3618819A4
Authority
EP
European Patent Office
Prior art keywords
combinations
methods
novel compositions
targeted drug
drug rescue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18794381.6A
Other languages
German (de)
English (en)
Other versions
EP3618819A1 (fr
Inventor
Sreenivasarao Vepachedu
Hans J. MOEBIUS
Anton Bespalov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exciva GmbH
Original Assignee
Exciva GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/048748 external-priority patent/WO2018039642A1/fr
Application filed by Exciva GmbH filed Critical Exciva GmbH
Publication of EP3618819A1 publication Critical patent/EP3618819A1/fr
Publication of EP3618819A4 publication Critical patent/EP3618819A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP18794381.6A 2017-05-04 2018-05-03 Targeted drug rescue avec de nouvelles compositions, associations et procédés correspondants Pending EP3618819A4 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762501696P 2017-05-04 2017-05-04
PCT/US2017/048748 WO2018039642A1 (fr) 2016-08-26 2017-08-25 Compositions et procédés associés
TW106129169A TW201815387A (zh) 2016-08-26 2017-08-28 組成物及其方法
US201862634162P 2018-02-22 2018-02-22
US201862636099P 2018-02-27 2018-02-27
US201862635554P 2018-02-27 2018-02-27
US201862636171P 2018-02-28 2018-02-28
PCT/US2018/030978 WO2018204713A1 (fr) 2017-05-04 2018-05-03 Targeted drug rescue avec de nouvelles compositions, associations et procédés correspondants

Publications (2)

Publication Number Publication Date
EP3618819A1 EP3618819A1 (fr) 2020-03-11
EP3618819A4 true EP3618819A4 (fr) 2021-01-20

Family

ID=65431106

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18794381.6A Pending EP3618819A4 (fr) 2017-05-04 2018-05-03 Targeted drug rescue avec de nouvelles compositions, associations et procédés correspondants

Country Status (13)

Country Link
EP (1) EP3618819A4 (fr)
JP (2) JP7514078B2 (fr)
KR (2) KR20200062078A (fr)
CN (1) CN110831584B (fr)
AU (2) AU2018261654A1 (fr)
BR (1) BR112019022902A2 (fr)
CA (2) CA3062452C (fr)
IL (1) IL270326B2 (fr)
MA (1) MA49464A (fr)
RU (1) RU2760558C9 (fr)
TW (1) TWI787260B (fr)
WO (1) WO2018204713A1 (fr)
ZA (1) ZA201908006B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021018564A2 (pt) * 2019-03-18 2021-11-30 Avanir Pharmaceuticals Inc Métodos de tratamento de sintomas negativos de esquizofrenia usando dextrometorfano deuterado e quinidina
KR20220018966A (ko) * 2019-06-06 2022-02-15 제이에스알 가부시끼가이샤 감방사선성 수지 조성물, 레지스트 패턴 형성 방법 및 화합물
EP4397371A2 (fr) 2020-05-19 2024-07-10 Cybin IRL Limited Dérivés de tryptamine deutérés et procédés d'utilisation
CN116473073A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法
CN116473077A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种n,n配位的镓配合物抗菌剂的合成和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006930A1 (fr) * 2002-07-17 2004-01-22 Avanir Pharmaceuticals Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
WO2014011590A2 (fr) * 2012-07-12 2014-01-16 Javitt Daniel C Composition et méthode pour le traitement de la dépression et de la psychose chez l'homme

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241065A (en) * 1979-07-02 1980-12-23 E. I. Du Pont De Nemours And Company Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6207674B1 (en) 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
CA2641392A1 (fr) 2006-02-03 2007-08-16 Avanir Pharmaceuticals Compositions pharmaceutiques comprenant du dextromethorphane et de la quinidine pour le traitement de la depression, de l'anxiete et des troubles neurodegeneratifs
EP2162135A4 (fr) * 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc Compositions, synthèses et procédés d'utilisation d'agents antipsychotiques atypiques à base de quinolinone
US8017623B2 (en) * 2008-07-03 2011-09-13 Trinity Laboratories, Inc. Dextromethorphan hydrochloride
US10716784B2 (en) 2013-03-07 2020-07-21 Mindlab LLC Pain medicine combination and uses thereof
AU2014232869A1 (en) 2013-03-15 2015-10-08 Patrizia Fanara Methods for monitoring the effects of an agent in sujects with motoneuron disease with dementia
US11103499B2 (en) * 2016-08-26 2021-08-31 EXCIVA (UG) (haftungsbeschränkt) Compositions and methods thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006930A1 (fr) * 2002-07-17 2004-01-22 Avanir Pharmaceuticals Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
WO2014011590A2 (fr) * 2012-07-12 2014-01-16 Javitt Daniel C Composition et méthode pour le traitement de la dépression et de la psychose chez l'homme

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOO-YEOUN CHO ET AL: "Selective Inhibition of Cytochrome P450 2D6 by Sarpogrelate and Its Active Metabolite, M-1, in Human Liver Microsomes", DRUG METABOLISM AND DISPOSITION, vol. 42, no. 1, 28 October 2013 (2013-10-28), US, pages 33 - 39, XP055674658, ISSN: 0090-9556, DOI: 10.1124/dmd.113.054296 *
MEIJUAN XU ET AL: "Effect of sarpogrelate hydrochloride on cytochrome P450 2D1/2 in rats", vol. 30, no. 12, 1 January 2014 (2014-01-01), pages 1739 - 1742, XP009519281, ISSN: 1001-1978, Retrieved from the Internet <URL:http://wprim.whocc.org.cn/admin/article/articleDetail?WPRIMID=458713&articleId=458713> DOI: 10.3969/J.ISSN.1001-1978.2014.12.024 *
SOO KYUNG BAE ET AL: "Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. Volume 10, 1 September 2016 (2016-09-01), pages 2959 - 2972, XP055674632, DOI: 10.2147/DDDT.S109141 *

Also Published As

Publication number Publication date
EP3618819A1 (fr) 2020-03-11
JP2023143940A (ja) 2023-10-06
AU2018261654A1 (en) 2019-11-14
JP7514078B2 (ja) 2024-07-10
JP2020518617A (ja) 2020-06-25
TW201842902A (zh) 2018-12-16
KR20200062078A (ko) 2020-06-03
RU2019137004A3 (fr) 2021-06-04
CA3062452C (fr) 2023-10-24
IL270326B (en) 2022-10-01
IL270326B2 (en) 2023-02-01
RU2760558C9 (ru) 2022-02-22
ZA201908006B (en) 2021-04-28
CN110831584A (zh) 2020-02-21
CA3062452A1 (fr) 2018-11-08
CA3138116A1 (fr) 2018-11-08
CN110831584B (zh) 2023-03-10
MA49464A (fr) 2020-04-29
KR20210130827A (ko) 2021-11-01
RU2019137004A (ru) 2021-06-04
RU2760558C2 (ru) 2021-11-29
AU2021215274A1 (en) 2021-09-02
IL270326A (fr) 2018-05-03
KR102444803B1 (ko) 2022-09-19
WO2018204713A1 (fr) 2018-11-08
TWI787260B (zh) 2022-12-21
BR112019022902A2 (pt) 2020-05-19
AU2021215274B2 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
EP3463386A4 (fr) Oligonucléotides, compositions et méthodes associées
EP3665156A4 (fr) Composés, compositions et procédés
EP3313404A4 (fr) Compositions thérapeutiques, associations et procédés d&#39;utilisation
EP3485068A4 (fr) Procédés, dispositifs et compositions électrochimiques
EP3676297A4 (fr) Composés, compositions et procédés
EP3313530A4 (fr) Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci
EP3315608A4 (fr) Arnsi, composition pharmaceutique et conjugué contenant un arnsi, et utilisations de ces derniers
EP3297637A4 (fr) Dérivés de benzène-1,3,5-tricarboxamide et utilisations de ces dérivés
EP3161124A4 (fr) Endophytes, compositions associées et leurs méthodes d&#39;utilisation
EP3491026A4 (fr) Anticorps humains, compositions pharmaceutiques et procédés
EP3100731A4 (fr) Conjugué de médicaments cytotoxiques et de ligands, son procédé de préparation et ses applications
EP3618819A4 (fr) Targeted drug rescue avec de nouvelles compositions, associations et procédés correspondants
EP3137168A4 (fr) 4-phénylepipéridines substituées, leur préparation et utilisation
EP3131131A4 (fr) Élément électroluminescent et composition utilisée dedans
EP3723763A4 (fr) Conjugués anticorps anti-cd22-maytansine, associations et méthodes d&#39;utilisation correspondantes
EP3395366A4 (fr) Procédé de conception de médicament, médicament obtenu et application associée
EP3381925A4 (fr) Dérivés de brigatinib modifiés par deutérium, compositions pharmaceutiques les contenant et utilisation correspondante
EP3162835A4 (fr) Composition de monomère, et composition durcissable contenant celle-ci
EP3359676A4 (fr) Système de transposon, kit le comprenant et utilisations correspondantes
EP3699179A4 (fr) Dérivé tricyclique contenant du pyrazolyle, son procédé de préparation et son utilisation
EP3449924A4 (fr) Composition, site actif de crocines, et leurs utilisations
EP3166945A4 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
EP3239183A4 (fr) Polymère de diène conjugué modifié et composition de polymère contenant ledit polymère
HUE057073T2 (hu) Polibutadiének, azok elõállítása és alkalmazása
EP3212699A4 (fr) Compositions pour polymérisation en suspension, procédés et leur utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191203

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RAV Requested validation state of the european patent: fee paid

Extension state: MA

Effective date: 20191203

Extension state: TN

Effective date: 20191203

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40015233

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031135000

Ipc: A61K0031138000

A4 Supplementary search report drawn up and despatched

Effective date: 20201217

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/225 20060101ALI20201211BHEP

Ipc: A61K 47/60 20170101ALI20201211BHEP

Ipc: A61K 9/20 20060101ALI20201211BHEP

Ipc: A61K 47/36 20060101ALI20201211BHEP

Ipc: A61K 31/485 20060101ALI20201211BHEP

Ipc: A61K 31/195 20060101ALI20201211BHEP

Ipc: A61K 45/06 20060101ALI20201211BHEP

Ipc: A61K 31/13 20060101ALI20201211BHEP

Ipc: A61K 31/138 20060101AFI20201211BHEP

Ipc: A61P 25/00 20060101ALI20201211BHEP

Ipc: A61K 31/439 20060101ALI20201211BHEP

Ipc: A61P 9/00 20060101ALI20201211BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231123